This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 24/9/1696    most recent 01.ATV.0000135981.61827.9dv1 Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dichek, H. L. Articles by Agrawal, N. Search for Related Content PubMed PubMed Citation Articles by Dichek, H. L. Articles by Agrawal, N. Related Collections Animal models of human disease Pathophysiology Genetically altered mice Glucose intolerance Lipid and lipoprotein metabolism Mechanism of atherosclerosis/growth factors

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2004;24:1696.)
© 2004 American Heart Association, Inc.

Atherosclerosis and Lipoproteins

Divergent Effects of the Catalytic and Bridging Functions of Hepatic Lipase on Atherosclerosis

Helén L. Dichek; Kun Qian; Nalini Agrawal

From the Department of Pediatrics, University of Washington, Seattle, Wash.

Correspondence to Helén L. Dichek, Department of Pediatrics, Box 356320, University of Washington, 1959 NE Pacific Street, Seattle WA 98195. E-mail hdichek{at}u.washington.edu

Objective— Increased expression of human hepatic lipase (HL) or a catalytically inactive (ci) HL clears plasma cholesterol in mice deficient in low-density lipoprotein receptors (LDLr) and murine HL. We hypothesized that increased expression of both HL and ciHL reduces atherosclerosis in these mice.

Methods and Results— Mice deficient in both LDLr and murine HL, alone or transgenically expressing similar levels of either human HL or ciHL, were fed a high-fat, cholesterol-enriched "Western" diet for 3 months to accelerate the development of atherosclerosis. Levels of plasma lipids, insulin, glucose, and liver enzymes were measured monthly, and aortic atherosclerosis was quantitated after 3 months. Plasma insulin, glucose, and liver enzyme levels did not differ significantly from controls. After 3 months, expression of HL reduced plasma cholesterol by 55% to 65% and reduced atherosclerosis by 40%. Surprisingly, expression of ciHL did not reduce plasma cholesterol or atherosclerosis.

Conclusions— High levels of HL, but not ciHL, delay the development of atherosclerosis in mice deficient in LDLr and mHL.

These studies demonstrate that high levels of catalytically active human hepatic lipase (HL) reduce atherosclerosis, whereas high levels of a catalytically inactive HL do not affect atherosclerosis in mice genetically deficient in low-density lipoprotein receptor and mouse HL.

Key Words: hepatic lipase • atherosclerosis • bridging function • fatty liver • mouse models

This article has been cited by other articles:

				L. Freeman, M. J. A. Amar, R. Shamburek, B. Paigen, H. B. Brewer Jr., S. Santamarina-Fojo, and H. Gonzalez-Navarro Lipolytic and ligand-binding functions of hepatic lipase protect against atherosclerosis in LDL receptor-deficient mice J. Lipid Res., January 1, 2007; 48(1): 104 - 113. [Abstract] [Full Text] [PDF]

				H. L. Dichek, N. Agrawal, N. E. Andaloussi, and K. Qian Attenuated corticosterone response to chronic ACTH stimulation in hepatic lipase-deficient mice: evidence for a role for hepatic lipase in adrenal physiology Am J Physiol Endocrinol Metab, May 1, 2006; 290(5): E908 - E915. [Abstract] [Full Text] [PDF]

				S. L. Karackattu, B. Trigatti, and M. Krieger Hepatic Lipase Deficiency Delays Atherosclerosis, Myocardial Infarction, and Cardiac Dysfunction and Extends Lifespan in SR-BI/Apolipoprotein E Double Knockout Mice Arterioscler Thromb Vasc Biol, March 1, 2006; 26(3): 548 - 554. [Abstract] [Full Text] [PDF]